It is reported that in clinics and mouse model of chronic hepatitis and fibrosis, blockade of IL-22 attenuated hepatic expression of CXC10 and CCL20 and subsequently reduced Th17 recruitment and liver inflammation and fibrosis progression. Here, CCL20 is linked to chronic hepatitis.